tirzepatide diabetes trial once weekly for the treatment of obesity in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 tirzepatide clinical trial enrollment A

In the Phase 2 trial protocol, participants began at a low starting dose commonly 2 mg once weekly before progressing through incremental increases over several months, with target maintenance doses ranging from 8 mg to 12 mg weekly depending on tolerability and clinical response

Most providers recommend a gradual transition rather than an abrupt switch to prevent gaps in GLP-1 coverage

Raffaelli M, Iaconelli A, Nanni G, et al

That means your body absorbs less than 1% of what you swallow

In this detailed guide, we will explore the science behind Trulicity, how it aids in weight loss, and how to determine the right dosage for you